Mankind Pharma Ki Q4 Earnings: Profit **32%** Bhaga, Revenue Bhi Bada!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Mankind Pharma Ki Q4 Earnings: Profit **32%** Bhaga, Revenue Bhi Bada!
Overview

Mankind Pharma ne Q4 mein kamaal kar diya! Net profit **31.7%** badhkar **₹554 Crore** ho gaya. Revenue bhi **11.8%** badhkar **₹3,443 Crore** pahuncha, aur margins bhi **27%** tak sudhre. Company ne **₹500 Crore** ka investment bhi approve kiya hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Mankind Pharma ne Q4 mein apna financial performance badiya rakha hai. Net profit 31.7% badhkar ₹554 Crore ho gaya, last year isi quarter mein yeh ₹421 Crore tha. Revenue bhi 11.8% increase hokar ₹3,443 Crore pahunch gaya, jo pehle ₹3,079 Crore tha.

Margin Badhne Se Profitability Ki Dhajjiyaan

Operating income (EBIT) mein 36.1% ka jabardast jump aaya, jo ₹930 Crore tak pahunch gaya. Margins bhi 27% ho gaye hain March quarter mein, jo last year 22.2% the. Iska matlab company ab zyada efficient ho gayi hai.

Naye Investments Aur Board Mein Changes

Iske alawa, board ne subsidiary Mankind Medicare mein ₹500 Crore aur invest karne ka faisla kiya hai. Satish Kumar Sharma ko 5 saal ke liye Whole-Time Director banaya gaya hai, jisse company ki leadership aur mazboot hogi.

Market Reaction

Yeh results Tuesday ko market band hone ke baad aaye. Mankind Pharma ka stock 0.12% girkar ₹2,492.6 par band hua, jo NSE Nifty 50 index se thoda kam hai. Saal mein ab tak stock 13.48% badha hai, lekin pichhle 12 mahino mein 2.79% gira hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.